Ambrisentan, a non-peptide endothelin receptor antagonist
about
EndothelinClinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentanActivation mechanism of endothelin ETB receptor by endothelin-1AmbrisentanEndothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome.High-performance liquid chromatography tandem mass spectrometry method for quantification of endothelin receptor antagonist drug, ambrisentan, in human plasma and its application in a pharmacokinetic study.Vasoactive peptides in cardiovascular (patho)physiology.Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?Leads for the treatment of pulmonary hypertension.Ambrisentan for the treatment of pulmonary arterial hypertensionPharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.Metal-free hydroarylation of the side chain carbon-carbon double bond of 5-(2-arylethenyl)-3-aryl-1,2,4-oxadiazoles in triflic acid.Atrasentan for the treatment of diabetic nephropathy.Stability-Indicating RP-HPLC Method for the Determination of Ambrisentan and Tadalafil in Pharmaceutical Dosage Form.Extractive spectrophotometric determination of ambrisentan.Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.Efficacy and safety of darusentan: a novel endothelin receptor antagonist.X-ray structures of endothelin ETB receptor bound to clinical antagonist bosentan and its analog.Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?Rapid determination of ambrisentan enantiomers by enantioselective liquid chromatography using cellulose-based chiral stationary phase in reverse phase mode.Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
P2860
Q26767156-F9224FD1-E089-4126-BF58-B2C856BBE646Q26851546-47B63D66-791E-443B-9880-1A38EDB044DDQ27727996-938BFF5A-B7AC-4B1A-8B28-21CD624EC092Q28238985-E2C6E86A-49B9-4800-99D0-285A71B690EFQ28246158-283DA496-6D29-4297-A4D9-804CCAE31E12Q34360718-4EC059B9-8EE4-4BD9-BF69-5C886C3D9830Q35116895-9552C3D4-E985-4462-B5C9-372D93E397C3Q36815987-26295BFB-B125-4CC8-88D7-AEDBDBBB143CQ36836706-AD6A01A3-61D3-414D-99A8-312A484093F5Q37481343-F0896EAF-9898-4AA5-8CEC-D547AE448A50Q37634323-09C369C6-E1A3-4A8E-A1A7-82AAB4AF8DEAQ38325919-242B866E-5E22-4563-B7F5-55FE1F4E8999Q38762666-2B17424E-73F3-4195-A548-08B2F2AAAE84Q38806647-D6D613B7-14C6-4BFE-9A9E-22E48AF5E9B9Q41410888-66E0ECCE-F99C-4033-9AF7-9C4B4A2D5FADQ42012949-1F2CB993-C380-4E95-9CE4-2FF6AFCE2889Q42971222-C6B4BF7A-7E53-4CF9-951C-57E2C4E33575Q45973623-F3154322-EC3D-4952-9C0C-70AC39491739Q47929318-D14B3681-5842-4DA9-B70B-62FACD5D5A53Q48096475-A3D1F733-9CF5-4D39-844D-C61FB7730A01Q53131404-89DC827A-8349-409B-9F20-BF99B6A0123AQ57484162-405ECF5F-0EB9-4934-8CA9-E9B4729BC388
P2860
Ambrisentan, a non-peptide endothelin receptor antagonist
description
2006 nî lūn-bûn
@nan
2006 թուականին հրատարակուած գիտական յօդուած
@hyw
2006 թվականին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Ambrisentan, a non-peptide endothelin receptor antagonist
@ast
Ambrisentan, a non-peptide endothelin receptor antagonist
@en
Ambrisentan, a non-peptide endothelin receptor antagonist
@nl
type
label
Ambrisentan, a non-peptide endothelin receptor antagonist
@ast
Ambrisentan, a non-peptide endothelin receptor antagonist
@en
Ambrisentan, a non-peptide endothelin receptor antagonist
@nl
prefLabel
Ambrisentan, a non-peptide endothelin receptor antagonist
@ast
Ambrisentan, a non-peptide endothelin receptor antagonist
@en
Ambrisentan, a non-peptide endothelin receptor antagonist
@nl
P2860
P3181
P1476
Ambrisentan, a non-peptide endothelin receptor antagonist
@en
P2093
Hartmut Vatter
Volker Seifert
P2860
P3181
P356
10.1111/J.1527-3466.2006.00063.X
P407
P577
2006-01-01T00:00:00Z